The also claim significant effects for hand grip and quality of life but they tested so many variables (including VO2 peak and fatigue severity, which showed no effect) and did not control for multiple testing.
The trial design was also A versus A + B, with the control group receiving no...
MCID estimates are a bit imprecise and vague, so not arguing that one is necessarily better than the other. But it seemed that they changed their MCID choice after seeing the data, without explaining this in their paper.
The correct way would probably to argue that their result may or may not...
Similar to a previous exercise study found an effect of 36.4 meter on the primary outcome the incremental shuttle walk test. They argue that "The effect size exceeded the minimum clinically important difference of 35.0 m [13]"
But in the power calculation in their protocol, they used a minimal...
Now published, see post #9
--------------------------------------------
Abstract
Long COVID, reflected by persistent symptoms, including breathlessness and fatigue, after coronavirus disease-19 (COVID-19) infection, presents an unmet therapeutic need. In this study, the effects of a resistance...
Which is much lower than the 50% that some advocates use (often based on the flawed review linked below):
https://www.s4me.info/threads/the-persistence-of-me-cfs-after-sars-cov-2-infection-a-systematic-review-and-meta-analysis-2024-dehlia-et-al.40426/#post-556430
Looked at some of these studies like Li 2022 or Romanet 2023 and they focused on patients discharged from hospital with pulmonary problems so quite different from the ME/CFS subtype of Long Covid.
Don't quite understand what you mean by this? Isn't the problem simply that these trials did not include a non-exercise control group (and thus cannot estimate the effect of exercise)?
There is a new comment by Lillebeth Larun, the primary author:
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003200.pub9/detailed-comment/en?messageId=451624933
On Twitter Wigglethemouse also suggested this study as problematic:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Kurup+RK%5BAuthor%5D+digoxin%5BTitle%5D
And the Perez study using 23 and ME data:
Genetic Predisposition for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study 2019...
Yes it's quite helpful to see the distribution of fatigue scores. The mean was no different between groups: both around 13 which is rather low for the Chalder Fatigue Scale (0-33). In comparison participants of the PACE trial had a score near 28.
But the Sars-Cov-2 positives seem to have...
Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disorder characterized by serious physical and cognitive impairments. Recent research underscores the role of immune dysfunction, including the role of autoantibodies, in ME/CFS pathophysiology. Expanding on...
Seems to be the case for the proportion that report fatigue and headache, which did not increase much in the COVID-19[+]PS group as it was already high. For shortness of breath there is a strong increase.
Persistent symptoms following Sars-Cov-2 infection were defined as reporting "both shortness of breath and fatigue at least five times after their positive SARS-CoV-2 test."
Based on these criteria you would expect that they exclude patients with fatigue and shortness of breath at the study...
Side-thought: it must be really frustrating to be a true scientist amongst this mess of fraud and incompetence. Imagine funding going to 'exciting' but totally untrustworthy or incredible studies over and over again, while valuable work gets overlooked. Promotions going to people with 50...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.